Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, and Monoclonal and Polyclonal Antibodies Research.
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
Impact of postoperative complications on clinical outcomes after gastrectomy for cancer: multicentre study
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline
Defining benchmarks for total and distal gastrectomy: global multicentre analysis
Disentangling oncogenic amplicons in esophageal adenocarcinoma
Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Genomic profiling for clinical decision making in lymphoid neoplasms
An <i>EZH2</i> Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of <i>EZH2</i> Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial
Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)
Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
Pooled analysis of 1‐year recall data from three root canal treatment outcome studies undertaken using cone beam computed tomography
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
The detection of periapical pathoses using digital periapical radiography and cone beam computed tomography in endodontically retreated teeth – part 2: a 1 year post‐treatment follow‐up
Obinutuzumab in hematologic malignancies: Lessons learned to date
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas